These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14215189)

  • 1. AGGLUTINATING, LETHAL TOXIN AND E1 TOR HAEMOLYSIN NEUTRALIZING POTENCY OF SERA IN CHOLERA.
    FELSENFELD O; NASUNIYA N; WATANABE Y; PENA A; DALE BN
    Bull World Health Organ; 1964; 30(6):833-44. PubMed ID: 14215189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies on the cholera toxin and antitoxin.
    Ungar J; Stanić M; Varallyay SJ; Chariatte N
    Prog Immunobiol Stand; 1970; 4():583-9. PubMed ID: 4099025
    [No Abstract]   [Full Text] [Related]  

  • 3. THE 1961 CHOLERA EPIDEMIC IN MANILA, REPUBLIC OF THE PHILIPPINES.
    WALLACE CK; FABIE AE; MANGUBAT O; VELASCO E; JUINIO C; PHILLIPS RA
    Bull World Health Organ; 1964; 30(6):795-810. PubMed ID: 14215186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Titration of cholera antitoxin in human sera by microhemagglutination with formalinized erythrocytes.
    Hochstein HD; Feeley JC; DeWitt WE
    Appl Microbiol; 1970 May; 19(5):742-5. PubMed ID: 5463574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective activity of cholera vaccines against E1 Tor cholera vibrios.
    PITTMAN M; FEELEY JC
    Bull World Health Organ; 1963; 28(3):379-83. PubMed ID: 13943861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Utilization of serological methods in the retrospective diagnosis of cholera and in detecting vibrion carriers].
    Bunin KV; Firsanov VI; Kravtsov EG; Nechaeva IP; Efimov DD
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Oct; (10):98-101. PubMed ID: 1210898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANTIHEMOLYSIN ACTIVITY OF SERA OF E1 TOR CHOLERA PATIENTS.
    ARAGON PR; FAMATIGA EG
    Am J Trop Med Hyg; 1963 Nov; 12():893-4. PubMed ID: 14072446
    [No Abstract]   [Full Text] [Related]  

  • 8. [Differences in certain immunological indices among persons who have had cholera and among Vibrio carriers].
    Bunin KV; Nechaeva IP; Flerova NK; Kravtsov EG; Venknevich BK
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Sep; 0(9):29-32. PubMed ID: 1199587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.
    Cash RA; Music SI; Libonati JP; Craig JP; Pierce NF; Hornick RB
    J Infect Dis; 1974 Oct; 130(4):325-33. PubMed ID: 4443613
    [No Abstract]   [Full Text] [Related]  

  • 10. STUDIES ON THE ROLE OF ACTIVE IMMUNIZATION IN THE PREVENTION OF CHOLERA EL TOR.
    BERAN GW; ELVINA O; FLORENDO FN
    J Philipp Med Assoc; 1964 Feb; 40():122-35. PubMed ID: 14244111
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholera toxoid boosts serum Escherichia coli antitoxin in humans.
    Nalin DR; al-Mahmud A; Curlin G; Ahmed A; Peterson J
    Infect Immun; 1974 Oct; 10(4):747-9. PubMed ID: 4609909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic specificity of neutralizing antibody to cholera toxin.
    Peterson JW; Hejtmancik KE; Markel DE; Craig JP; Kurosky A
    Infect Immun; 1979 Jun; 24(3):774-9. PubMed ID: 89089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of antibody responses and protective immunity in cholera vaccinated subjects.
    Chaicumpa W; Pacharaprakiti C; Plueksawan W; Atthasishtha N
    Southeast Asian J Trop Med Public Health; 1980 Mar; 11(1):58-66. PubMed ID: 7403955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial and antitoxin responses in the serum and milk of cholera patients.
    Majumdar AS; Dutta P; Dutta D; Ghose AC
    Infect Immun; 1981 Apr; 32(1):1-8. PubMed ID: 7216479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFECTS OF CHOLERA VACCINATION ON CLINICAL SYMPTOMS' OF EL-TOR VIBRIO INFECTION.
    CHAN YP; SUN TT; TSAI SY; WONG CC
    Tsa Chih Gaoxiong Yi Xue Yuan Tong Xue Hui; 1964 Feb; 63():80-4. PubMed ID: 14201560
    [No Abstract]   [Full Text] [Related]  

  • 17. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Preliminary report; Philippines Cholera Committee.
    Philippines Cholera Committee
    Bull World Health Organ; 1965; 32(5):603-25. PubMed ID: 5294176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolysin and the multifunctional autoprocessing RTX toxin are virulence factors during intestinal infection of mice with Vibrio cholerae El Tor O1 strains.
    Olivier V; Haines GK; Tan Y; Satchell KJ
    Infect Immun; 2007 Oct; 75(10):5035-42. PubMed ID: 17698573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRELIMINARY STUDIES ON THE DEVELOPMENT OF A LIVE ORAL VACCINE FOR ANTI-CHOLERA IMMUNIZATION.
    MUKERJEE S
    Bull World Health Organ; 1963; 29(6):753-66. PubMed ID: 14107748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of a standard reference cholera antitoxin.
    Craig JB
    Dev Biol Stand; 1978; 41():415-22. PubMed ID: 753669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.